Find a Clinical Trial

Showing 21 - 30 of 49 Trials

A Phase 1 Study of AGEN2373, an Anti-CD137 Monoclonal Antibody, as Monotherapy and in Combination with AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Patients with Advanced Cancer

Principal Investigator:

Richard D Carvajal, MD

Contact Number:

212-342-5162

NCT Number:

NCT04121676

Population:

Adult

Phase:

I

This research study is studying a drug called AGEN2373 as a possible treatment for advanced cancer. The study drug targets cells that are a part of the body’s immune system to block a protein called anti-CD137 agonist antibody. Blocking this protein is believed to improve the ability of your immune system to fight your cancer. This drug has been tested in animals. This is the first time that the Study Drug will be given to humans. The study will also evaluate how the body breaks down the study drug (pharmacokinetics or “PK”) and what is the effect of the study drug on the...
A Phase 1/1b Study of MPT-0118 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Solid Tumors

Principal Investigator:

Shaheer A Khan, DO

Contact Number:

212-342-5162

NCT Number:

NCT04859777

Population:

Adult

Phase:

I

The purpose of this study is to see if the investigational drug MPT-0118 is effective in treating people with cancer. This is the first time the study drug, MPT-0118, will be given to humans. MPT-0118 will be given alone (monotherapy) and in combination with Keytruda (pembrolizumab). Pembrolizumab is approved by the FDA to treat certain types of cancer. MPT- 0118 and Pembrolizumab are called immunotherapies, which are designed to activate your immune system to try to kill cancer cells. Are you Eligible? (Inclusion Criteria) Aged 18 years or older. Has been diagnosed with metastatic or...
Phase 1 Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 in Patients with Advanced Solid Tumors (MYTHIC Study)

Principal Investigator:

Ryan H. Moy, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT04855656

Population:

Adult

Phase:

I

The purpose of this research study is to test how safe RP-6306 is at different doses and schedules, test how well RP-6306 works to shrink cancer in the body, and evaluate if food affects the way RP-6306 moves through your body. This study will test the investigational drug, RP-6306, for the first time in humans. “Investigational” means that the study drug being tested has not been approved by the United States Food and Drug Administration (FDA). RP- 6306 is a PKMYT1 inhibitor (blocks the activity of the PKMYT1 protein) that is designed to stop certain cancer cells from growing...
Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors (MAGNETIC Study)

Principal Investigator:

Ryan H. Moy, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT05147272

Population:

Adult

Phase:

I

The purpose of this study is to learn how well RP-6306 (“study drug”) in combination with gemcitabine works to treat certain types of cancer. RP-6306 is a drug that is designed to stop certain cancer cells from growing by blocking a protein called PKMYT1. It is an investigational drug, which means that it has not been approved by any regulatory authorities, including the FDA. It is taken by mouth. RP-6306 (alone) has been given to patients in an ongoing study to understand how safe and effective it is. This is the first time RP-6306 is being given with gemcitabine to humans. Are...
An Open-Label, Phase II Multicenter Study of Rituximab or Tocilizumab for Steroid-Dependent Immune-Related Adverse Events due to Immune Checkpoint Blockade.

Principal Investigator:

Brian Henick, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT04375228

Population:

Adult

Phase:

II

The purpose of this study is to determine the safety and effectiveness of two drugs, either rituximab or tocilizumab, in patients who develop side effects while on treatment with immunotherapy requiring prolonged steroids. Immune-related side effects are caused by activation of the immune system from treatment with immunotherapy. Both rituximab and tocilizumab have been given to patients with autoimmune diseases (diseases where the immune system is activated against normal organs). Immune-related side effects appear to closely mirror these autoimmune conditions. Are you Eligible? (Inclusion...
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Principal Investigator:

Richard D Carvajal, MD

Contact Number:

212-342-5162

NCT Number:

NCT02693535

Population:

Adult

Phase:

II

Many research studies are done to try to find the best way to treat patients with cancer. Researchers are working on new anticancer agents that are targeted to the genes in a person’s tumor. Genes are the basic “instruction book” for the cells that make up our bodies and are made out of DNA. DNA contains information that determines things such as eye and hair color. DNA is made up of long strands of repeating letters that form a code. The order of these letters in DNA is important. In the same way that a spelling mistake in a word could change its meaning (for example, mean...
A Phase 1-2 dose-escalation and expansion study of ST101 in patients with advanced unresectable and metastatic solid tumors

Principal Investigator:

Fabio M. Iwamoto, MD

Contact Number:

212-342-5162

NCT Number:

NCT04478279

Population:

Adult

Phase:

I/II

With this research study, we want to find out which dose of ST101 is tolerable and effective for people with different types of cancer. We also want to see what the body does to ST101, where ST101 goes in the body, and how long it stays in the body. This study is the first time we have given ST101 to humans. Drugs that can only be used in research are sometimes called 'investigational drugs.' Investigational means the study drug/formulation/medical device being tested is not approved by the U.S. Food and Drug Administration (FDA). Are you Eligible? (Inclusion Criteria) Are you at least 18...
LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety andTolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patientswith an Advanced Solid Tumor

Principal Investigator:

Ryan H. Moy, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT04939610

Population:

Adult

Phase:

I/II

The purpose of this study is to test the safety of the experimental drugs called 68Ga-FAP-2286 and 177Lu-FAP-2286. 8Ga-FAP-2286 is an imaging agent that targets a certain protein which has been found in certain tumors called Fibroblast activation protein (FAP). Imaging using 68Ga-FAP-2286 will determine if participants are eligible to receive the experimental radiotherapy, 177Lu-FAP-2286, which researchers think may kill cancer cells by delivering radiation to cancer cells that have fibroblast activation protein (FAP). Are you Eligible? (Inclusion Criteria) Have you been diagnosed with...
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects with Wild-Type TP53 Advanced Solid Tumors

Principal Investigator:

Gary K Schwartz, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT03975387

Population:

Adult

Phase:

I/II

The purpose of the study is to test the following: 1) The safety and tolerability (how you feel when you take the drug) of the study drug, 2) The pharmacokinetics (PK) (how the study drug is absorbed within your body, spread throughout your body, and eliminated from your body) of the study drug, 3) The pharmacodynamics (PD) (how the study drug affects certain proteins related to your cancer) of the study drug, 4) The initial clinical effect (how the study drug affects your cancer) of the study drug, and 5) To determine the most appropriate dose (strength) and how often the drug should be...
A Phase 1 Open-label, Multicenter Study of MK-2118 Administered by Intratumoral Injection as Monotherapy and in Combination with Pembrolizumab or by Subcutaneous Injection in Combination with Pembrolizumab for Patients with Advanced/Metastatic Solid

Principal Investigator:

Matthew A. Ingham, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT03249792

Population:

Adult

Phase:

I

The purpose of this study is to: • test the safety of the study drug and see how your body handles it • find the highest dose of the study drug that can be given alone or in combination with pembrolizumab (MK-3475) with the least risk of serious side effects The study drug is called MK-2118. Are you Eligible? (Inclusion Criteria) Have confirmed solid tumor or lymphoma cancer. Participants may or may not have had treatment for their disease before. Have stage 3 or stage 4 disease that cannot be removed by surgery. Participants must be in good physical shape. This means that...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages